MCID: VGN020
MIFTS: 48

Vaginal Disease

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vaginal Disease

MalaCards integrated aliases for Vaginal Disease:

Name: Vaginal Disease 11 14 75
Vaginal Diseases 41 43 71

Classifications:



External Ids:

Disease Ontology 11 DOID:121
MeSH 43 D014623
NCIt 49 C26910
SNOMED-CT 68 25658005
UMLS 71 C0042251

Summaries for Vaginal Disease

MedlinePlus: 41 Vaginal problems are some of the most common reasons women go to the doctor. They may have symptoms such as: Itching Burning Pain Abnormal bleeding Discharge One common problem is vaginitis, an inflammation of the vagina. Other problems that affect the vagina include sexually transmitted diseases, vaginal cancer, and vulvar cancer. Treatment of vaginal problems depends on the cause.

MalaCards based summary: Vaginal Disease, also known as vaginal diseases, is related to vaginal discharge and vaginitis, and has symptoms including pelvic pain and leukorrhea. An important gene associated with Vaginal Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Acetylcysteine and Etonogestrel have been mentioned in the context of this disorder. Affiliated tissues include vagina, uterus and cervix, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A female reproductive system disease that is located in the vagina.

Related Diseases for Vaginal Disease

Diseases related to Vaginal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 859)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 31.1 TNF SLPI IL6 IL1B IL1A IL10
2 vaginitis 30.3 TNF TLR4 TLR2 SLPI IL6 IL1B
3 genital herpes 29.9 TNF TLR2 CD4 CCR6 CCR5
4 leukoplakia of vagina 10.9
5 cholesteatoma of external ear 10.4 IL1A CXCL8
6 external pathological resorption 10.4 TNF IL6
7 senile entropion 10.4 TNF CXCL8
8 histiocytosis 10.4 TNF IL17A CCR6
9 mycobacterium chelonae 10.4 TLR2 CXCL8
10 acute pericementitis 10.4 IL6 IL1B CXCL8
11 physiological polycythemia 10.4 TNF IL6 IL1B
12 periodontitis, chronic 10.4 IL6 IL1B
13 micropapillomatosis labialis 10.4 ESR1 CD4
14 vulvar squamous papilloma 10.4 ESR1 CD4
15 suppurative periapical periodontitis 10.4 IL6 IL1B CXCL8
16 chronic apical periodontitis 10.4 TNF IL6 IL1B
17 indolent plasma cell myeloma 10.4 IL6 IL1B IL1A
18 frozen shoulder 10.4 TNF IL6 IL1B
19 graves ophthalmopathy 10.4 TNF IL6 IL1B
20 carbuncle 10.4 TNF IL6 IL1B
21 fuchs' heterochromic uveitis 10.4 IL6 IL10 CXCL8
22 diabetic encephalopathy 10.4 TNF IL6 IL1B
23 mycobacterium marinum 10.4 TLR2 CXCL8
24 kashin-beck disease 10.4 TNF IL1B
25 oral hairy leukoplakia 10.4 SLPI IL10 CD4
26 pollen allergy 10.4 IL10 CD4 CCR6
27 type 1 diabetes mellitus 23 10.4 TNF CD4
28 gingival recession 10.4 TNF IL6 IL1B
29 retinal vasculitis 10.4 TNF CD4 CCR6
30 miller fisher syndrome 10.4 TNF IL6 CCR6
31 egg allergy 10.4 IL10 CD4 CCR6
32 plantar fascial fibromatosis 10.4 IL6 IL1B IL10
33 penicilliosis 10.4 CLEC7A CD4 CARD9
34 autoimmune cholangitis 10.4 IL17A CD4 CCR6
35 legume allergy 10.4 IL10 CD4 CCR6
36 infectious anterior uveitis 10.4 TNF IL17A
37 fruit allergy 10.4 IL10 CD4 CCR6
38 mycobacterium kansasii 10.4 TLR2 CXCL8
39 ventilation pneumonitis 10.4 CRP CD4
40 osteosclerotic myeloma 10.4 IL6 IL1B
41 cerebral artery occlusion 10.4 TNF IL6 IL1B
42 syphilitic meningitis 10.4 CRP CD4
43 progressive relapsing multiple sclerosis 10.4 IL17A CD4 CCR6
44 childhood type dermatomyositis 10.4 TNF CD4 CCR6
45 peanut allergy 10.4 IL10 CD4 CCR6
46 tinea capitis 10.4 CLEC7A CD4 CARD9
47 opisthorchiasis 10.4 TNF IL1B CXCL8
48 glossitis 10.4 TNF IL6 IL1B
49 acute generalized exanthematous pustulosis 10.4 IL17A CXCL8
50 corneal abscess 10.4 SLPI DEFB4A

Graphical network of the top 20 diseases related to Vaginal Disease:



Diseases related to Vaginal Disease

Symptoms & Phenotypes for Vaginal Disease

UMLS symptoms related to Vaginal Disease:


pelvic pain; leukorrhea

GenomeRNAi Phenotypes related to Vaginal Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 CARD9 CCL4L1 CCR5 CCR6 CD4 CLEC7A
2 no effect GR00402-S-2 10.14 CCL4L1 CCR5 CCR6 CD4 CLEC7A CRP

MGI Mouse Phenotypes related to Vaginal Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 CARD9 CCR5 CCR6 CD4 CLEC7A CRP
2 immune system MP:0005387 10.21 CARD9 CCR5 CCR6 CD4 CLEC7A CRP
3 neoplasm MP:0002006 10.13 CCR5 ESR1 IL10 IL1A IL1B IL6
4 digestive/alimentary MP:0005381 10.11 CCR5 CD4 CLEC7A ECE1 ESR1 IL10
5 cardiovascular system MP:0005385 10.1 CCR5 CCR6 CRP ECE1 ESR1 IL10
6 muscle MP:0005369 10.06 CCR5 ECE1 ESR1 IL10 IL6 TLR2
7 liver/biliary system MP:0005370 10.03 CCR5 ESR1 IL10 IL17A IL6 TLR2
8 hematopoietic system MP:0005397 9.89 CARD9 CCR5 CCR6 CD4 CLEC7A DEFB4A
9 respiratory system MP:0005388 9.81 CCR5 CLEC7A ESR1 IL10 IL17A IL6
10 integument MP:0010771 9.36 CD4 ECE1 ESR1 IL10 IL17A IL1A

Drugs & Therapeutics for Vaginal Disease

Drugs for Vaginal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
2
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Ethinylestradiol Approved Phase 4 57-63-6 5991
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Desflurane Approved Phase 4 57041-67-5 42113
8
Clindamycin Approved, Vet_approved Phase 4 18323-44-9, 24729-96-2 29029
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Azithromycin Approved Phase 4 83905-01-5 447043
11
Norethisterone Approved Phase 4 68-22-4 199472 6230
12
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
13
Chlorquinaldol Approved Phase 4 72-80-0 6301
14
Cysteine Approved, Nutraceutical Phase 4 52-90-4 594 5862
15
Norethindrone enanthate Experimental Phase 4 3836-23-5
16 Estrogens Phase 4
17 Expectorants Phase 4
18 Antidotes Phase 4
19 N-monoacetylcystine Phase 4
20 Respiratory System Agents Phase 4
21 Antioxidants Phase 4
22 Estrogens, Conjugated (USP) Phase 4
23 Estradiol 3-benzoate Phase 4
24 Estradiol 17 beta-cypionate Phase 4
25 Platelet Aggregation Inhibitors Phase 4
26 Anesthetics, Inhalation Phase 4
27 Anesthetics, General Phase 4
28 Anesthetics Phase 4
29
Clindamycin phosphate Phase 4 32603
30 Clindamycin palmitate Phase 4
31 Anti-Infective Agents, Local Phase 4
32 Pharmaceutical Solutions Phase 4
33 Cytochrome P-450 CYP3A Inhibitors Phase 4
34 Contraceptive Agents Phase 4
35 NuvaRing Phase 4
36 Contraceptives, Oral, Hormonal Phase 4
37 Contraceptives, Oral Phase 4
38
Norethindrone Acetate Phase 4 541197
39 Anti-Bacterial Agents Phase 4
40 Anti-Infective Agents Phase 4
41 Antiprotozoal Agents Phase 4
42 Antiparasitic Agents Phase 4
43
Formaldehyde Approved, Vet_approved Phase 3 50-00-0 712
44
Tamoxifen Approved Phase 3 10540-29-1, 54965-24-1 2733526
45
Fluocinolone acetonide Approved, Investigational, Vet_approved Phase 3 67-73-2 6215
46
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
47
Terconazole Approved Phase 3 67915-31-5 441383
48
Tinidazole Approved, Investigational Phase 3 19387-91-8 5479
49
Dequalinium Approved, Investigational Phase 3 6707-58-0 2993
50
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
3 Postmenopausal Pessary Users: Estrogen Versus Trimosan Unknown status NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
4 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
5 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
6 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
7 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo
9 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Completed NCT02042287 Phase 4 Metronidazole
10 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
11 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Completed NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
12 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
13 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Completed NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
14 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
15 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
16 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
17 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
18 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Completed NCT03937869 Phase 4 Secnidazole
19 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
20 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
21 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Completed NCT02905890 Phase 4 Norethisterone enantate
22 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
23 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT04771728 Phase 4 Metronidazole vaginal suppositories;Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)
24 A Randomized Controlled Trial of Treatment of Bacterial Vaginosis in Late Third Trimester to Prevent Maternal Peripartum Infection Terminated NCT04578015 Phase 4 Metronidazole;Placebo
25 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
26 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
27 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
28 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
29 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
30 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
31 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
32 Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women Completed NCT00729469 Phase 3 Ospemifene 60 mg;Placebo
33 Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo Completed NCT00566982 Phase 3 Ospemifene 60 mg;Placebo
34 Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo Completed NCT00276094 Phase 3 Ospemifene 30 mg;Ospemifene 60 mg;Placebo;Nonhormonal vaginal lubricant
35 Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310. Completed NCT01585558 Phase 3 Ospemifene (Dose 1);Ospemifene (Dose 2);Placebo
36 Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310 Completed NCT01586364 Phase 3 Ospemifene 60Mg Oral Tablet
37 A Phase 3 Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of DARE-BV1 in the Treatment of Bacterial Vaginosis Completed NCT04370548 Phase 3 DARE-BV1clindamycin phosphate vaginal gel, 2%
38 A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic) Completed NCT01867164 Phase 3 Gynoclin V;Vagitrol V
39 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
40 Home Screening for Bacterial Vaginosis to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole
41 Back to BASICS: Boric Acid, Alternate Solution for Intravaginal Colonization, Comparing Intravaginal Metronidazole to Boric Acid in Women Symptomatic for Bacterial Vaginosis Completed NCT00799214 Phase 2, Phase 3 Placebo;Boric acid;Metronidazole
42 Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219
43 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
44 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
45 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
46 A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. Completed NCT00229216 Phase 3 Tinidazole
47 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
48 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
49 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis. Completed NCT02236156 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
50 Randomized Controlled Trial of Treatment of Male Partners of Women With BV Completed NCT02209519 Phase 3 Metronidazole (male partner)

Search NIH Clinical Center for Vaginal Disease

Cochrane evidence based reviews: vaginal diseases

Genetic Tests for Vaginal Disease

Anatomical Context for Vaginal Disease

Organs/tissues related to Vaginal Disease:

FMA: Vagina
MalaCards : Uterus, Cervix, Breast

Publications for Vaginal Disease

Articles related to Vaginal Disease:

(show top 50) (show all 137)
# Title Authors PMID Year
1
Impacts of Menstruation, Community Type, and an Oral Yeast Probiotic on the Vaginal Microbiome. 62 41
36102507 2022
2
Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A randomized controlled trial. 41
36279690 2023
3
New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review. 41
35744033 2022
4
Antimicrobial Substances and Mechanisms of Lactobacillus rhamnosus against Gardnerella vaginalis. 62
36459386 2022
5
Outcomes of 3D MRI based HDR brachytherapy with hybrid multichannel vaginal cylinder applicator and freehand needles for treatment of vaginal disease. 62
36266203 2022
6
Factors Influencing Lower Limb Lymphedema After Cervical Cancer Surgery: A Case-Control Study. 62
35905037 2022
7
SIIV position paper: clinical approach to vulval diseases: need for quality standards. 62
35758091 2022
8
Mycoplasma genitalium and Chlamydia trachomatis infection among women in Southwest China: a retrospective study. 62
35734919 2022
9
Inhibitory effect of Lactobacillus gasseri CCFM1201 on Gardnerella vaginalis in mice with bacterial vaginosis. 62
35546374 2022
10
Characterization of a Novel Fructosyltransferase from Lactobacillus crispatus, InuCA, That Attaches to the Cell Surface by Electrostatic Interaction. 62
34910558 2022
11
Partial Vaginectomy, Complete Vaginectomy, Partial Vestibule-Vaginectomy, Vulvo-Vestibule-Vaginectomy and Vulvo-Vestibulectomy: Different Surgical Procedure in Order to Better Approach Vaginal Diseases. 62
35049818 2022
12
Vaginal high-grade sarcoma in pregnancy. 62
34926762 2021
13
Imaging of the Vagina: Spectrum of Disease with Emphasis on MRI Appearance. 62
34297630 2021
14
Current and emerging pharmacotherapy for recurrent bacterial vaginosis. 62
33750246 2021
15
Chitosan-based systems aimed at local application for vaginal infections. 62
33766328 2021
16
Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) as treatment for upper vaginal leiomyoma: A case report. 62
34011080 2021
17
Preliminary results of modified interstitial MIAMI brachytherapy applicator for treatment of upper and apical vaginal tumors. 62
33437304 2020
18
Promising Drug Delivery Approaches to Treat Microbial Infections in the Vagina: A Recent Update. 62
33374756 2020
19
Protocol for In Vitro Establishment and Long-Term Culture of Mouse Vaginal Organoids. 62
33111121 2020
20
Phosphoregulation of a Conserved Herpesvirus Tegument Protein by a Virally Encoded Protein Kinase in Viral Pathogenicity and Potential Linkage between Its Evolution and Viral Phylogeny. 62
32611749 2020
21
A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus. 62
32295919 2020
22
MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study. 62
31682968 2020
23
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China. 62
31897224 2020
24
Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. 62
31718338 2019
25
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. 62
31707496 2019
26
Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study. 62
31427275 2019
27
Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. 62
30650180 2019
28
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. 62
30982556 2019
29
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study. 62
30827725 2019
30
Newly Isolated Lactobacilli strains from Algerian Human Vaginal Microbiota: Lactobacillus fermentum Strains Relevant Probiotic's Candidates. 62
29185234 2019
31
Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. 62
30804128 2019
32
Can We Improve Vaginal Tissue Healing Using Customized Devices: 3D Printing and Biomechanical Changes in Vaginal Tissue. 62
30269139 2019
33
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome. 62
30384345 2018
34
Regulation of Herpes Simplex Virus 2 Protein Kinase UL13 by Phosphorylation and Its Role in Viral Pathogenesis. 62
29899106 2018
35
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 62
28886907 2017
36
Novel ex vivo protocol using porcine vagina to assess drug permeation from mucoadhesive and colloidal pharmaceutical systems. 62
28697437 2017
37
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. 62
28446260 2017
38
Vulvar and Vaginal Graft versus Host Disease: A Healthcare Clinic Initiative. 62
28503642 2017
39
Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. 62
28445274 2017
40
Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. 62
29017160 2017
41
Biotherapeutic agents and vaginal health. 62
26757173 2016
42
Baboon vaginal microbial flora. 62
27198467 2016
43
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. 62
27084683 2016
44
Magnetic resonance imaging of the vagina: an overview for radiologists with emphasis on clinical decision making. 62
26379324 2015
45
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. 62
25693011 2015
46
Clinical characteristics of non-squamous cell carcinoma of the vagina. 62
25594143 2015
47
Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. 62
25987893 2015
48
Spray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structure. 62
26347257 2015
49
Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer. 62
26442213 2015
50
[Group A streptococcal perineal infection in children]. 62
25456689 2014

Variations for Vaginal Disease

Expression for Vaginal Disease

Search GEO for disease gene expression data for Vaginal Disease.

Pathways for Vaginal Disease

Pathways related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TNF IL6 IL1B IL1A IL17A IL10
2
Show member pathways
13.86 TLR4 TLR2 IL6 IL1B IL1A IL17A
3
Show member pathways
13.69 CCL4L1 CCR5 CCR6 CD4 CXCL8 ECE1
4
Show member pathways
13.66 CARD9 CCL4L1 CCR5 CCR6 CD4 CLEC7A
5
Show member pathways
13.59 TNF IL6 IL1B IL1A IL17A IL10
6
Show member pathways
13.43 CCL4L1 CCR5 CD4 CXCL8 IL10 IL17A
7
Show member pathways
13.39 TNF IL6 IL1B IL1A IL17A IL10
8
Show member pathways
13.36 CCL4L1 CCR5 CCR6 CD4 CXCL8 IL10
9
Show member pathways
12.96 TNF TLR4 TLR2 IL6 IL1B IL1A
10
Show member pathways
12.89 CXCL8 CD4 CCR6 CCR5 CCL4L1
11
Show member pathways
12.81 TNF TLR4 TLR2 IL6 IL1B IL1A
12
Show member pathways
12.77 TNF IL6 IL1B IL1A IL17A IL10
13
Show member pathways
12.75 TNF TLR2 IL6 IL1B IL1A CXCL8
14
Show member pathways
12.73 CCR5 CD4 IL1A IL1B TNF
15
Show member pathways
12.7 TNF IL6 IL1B IL17A IL10 CD4
16
Show member pathways
12.68 IL1A IL1B TLR2 TLR4 TNF
17 12.68 CARD9 IL10 IL17A IL1B TLR2 TNF
18
Show member pathways
12.65 TNF TLR4 TLR2 IL6 IL1B CXCL8
19
Show member pathways
12.48 CXCL8 DEFB4A IL1A IL1B IL6 TLR2
20
Show member pathways
12.45 CXCL8 IL1A IL1B IL6 TLR4 TNF
21
Show member pathways
12.39 TNF TLR2 IL6 IL17A CXCL8
22
Show member pathways
12.36 TLR2 DEFB4A CD4 CCR6
23 12.27 TNF IL6 IL1B IL1A IL10 ECE1
24 12.25 TNF TLR4 TLR2 IL6
25 12.23 TNF IL6 IL1B IL1A IL10
26
Show member pathways
12.21 TNF IL17A IL10 CD4
27 12.14 CXCL8 IL1A IL1B IL6 TLR4 TNF
28
Show member pathways
12.13 CXCL8 CCR6 CCR5 CCL4L1
29
Show member pathways
12.11 IL1A IL1B TLR2 TLR4
30 12.09 TNF IL6 IL10 CD4
31
Show member pathways
12.06 IL1B CD4 CCR5 CCL4L1
32 12.05 CCR5 CCR6 CXCL8 IL10 IL6
33 12.04 IL6 IL1B IL1A CXCL8
34 12.01 TNF IL1B IL1A IL17A IL10 CXCL8
35 12.01 TNF IL6 IL1B IL1A IL17A IL10
36
Show member pathways
11.99 TLR4 TLR2 IL6 IL1B IL17A CD4
37
Show member pathways
11.98 TLR4 IL6 IL17A CXCL8
38 11.93 TNF IL1B IL17A IL10 CD4 CCR6
39 11.92 TNF TLR4 IL6 IL1B CXCL8
40 11.92 TLR4 IL6 IL10 CD4 CCR5
41 11.9 TNF IL6 IL1B IL10 CD4
42
Show member pathways
11.89 CD4 CRP CXCL8 IL6
43 11.88 CRP IL10 IL6 TLR4 TNF
44 11.84 IL6 IL1B IL17A CD4
45 11.84 IL6 IL10 ESR1 CXCL8
46
Show member pathways
11.81 TNF IL6 IL1B IL1A CXCL8
47 11.8 TNF IL6 IL1B CXCL8
48 11.78 TNF TLR4 IL6 IL1A IL10 CXCL8
49 11.76 TNF TLR4 IL6 IL1B IL1A IL10
50 11.72 TNF TLR4 IL6 DEFB4A CXCL8

GO Terms for Vaginal Disease

Cellular components related to Vaginal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.18 TNF SLPI IL6 IL1B IL1A IL17A
2 external side of plasma membrane GO:0009897 9.8 CCR5 CCR6 CD4 ECE1 IL17A TLR4
3 cell surface GO:0009986 9.5 TNF TLR4 TLR2 IL1A CLEC7A CD4

Biological processes related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.67 ESR1 IL10 IL17A IL1A IL1B IL6
2 signal transduction GO:0007165 10.64 TNF TLR4 TLR2 IL6 IL1B IL10
3 innate immune response GO:0045087 10.49 TLR4 TLR2 SLPI IL17A CRP CLEC7A
4 positive regulation of gene expression GO:0010628 10.48 CLEC7A CRP CXCL8 IL1A IL1B IL6
5 negative regulation of cell population proliferation GO:0008285 10.46 TNF TLR2 IL6 IL1B IL1A IL10
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.38 CARD9 CCL4L1 CD4 IL1A TLR4 TNF
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.36 CARD9 CD4 CLEC7A IL1A IL1B TLR4
8 defense response to bacterium GO:0042742 10.33 TNF TLR4 SLPI IL10 DEFB4A
9 positive regulation of inflammatory response GO:0050729 10.32 TNF TLR4 TLR2 IL1B
10 positive regulation of DNA-binding transcription factor activity GO:0051091 10.31 TNF IL6 IL1B IL10 ESR1 CLEC7A
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.31 TNF TLR4 TLR2 IL6 IL1B CLEC7A
12 positive regulation of JNK cascade GO:0046330 10.3 TNF TLR4 IL1B IL1A CARD9
13 positive regulation of type II interferon production GO:0032729 10.29 CLEC7A IL1B TLR4 TNF
14 positive regulation of tumor necrosis factor production GO:0032760 10.28 TLR4 TLR2 IL6 IL1A IL17A CLEC7A
15 cellular response to lipopolysaccharide GO:0071222 10.28 CCR5 CXCL8 IL10 IL1A IL1B IL6
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.27 TNF TLR4 TLR2 IL1B
17 calcium-mediated signaling GO:0019722 10.27 TNF CXCL8 CD4 CCR6 CCR5
18 defense response to Gram-negative bacterium GO:0050829 10.27 TLR4 IL6 IL17A DEFB4A CD4
19 JNK cascade GO:0007254 10.26 CARD9 IL1B TLR4 TNF
20 cellular response to type II interferon GO:0071346 10.25 TNF TLR4 TLR2 CCL4L1
21 positive regulation of interleukin-1 beta production GO:0032731 10.25 CLEC7A IL17A IL6 TLR4 TNF
22 chemokine-mediated signaling pathway GO:0070098 10.23 CXCL8 CCR6 CCR5 CCL4L1
23 positive regulation of interleukin-12 production GO:0032735 10.23 TLR4 TLR2 IL17A CLEC7A
24 positive regulation of interleukin-8 production GO:0032757 10.23 CLEC7A IL1B IL6 TLR2 TLR4 TNF
25 positive regulation of nitric oxide biosynthetic process GO:0045429 10.22 TNF TLR4 IL1B CLEC7A
26 defense response to Gram-positive bacterium GO:0050830 10.22 CARD9 CRP DEFB4A IL17A IL1B IL6
27 inflammatory response GO:0006954 10.22 TNF TLR4 TLR2 IL6 IL1B IL1A
28 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.21 TNF IL1B IL1A
29 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.21 TNF IL6 IL10
30 immune system process GO:0002376 10.21 CARD9 CD4 CLEC7A IL17A SLPI TLR2
31 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.21 TNF TLR4 IL1B CARD9
32 positive regulation of interleukin-10 production GO:0032733 10.21 CLEC7A IL6 TLR2 TLR4
33 lipopolysaccharide-mediated signaling pathway GO:0031663 10.21 TNF TLR4 TLR2 IL1B
34 positive regulation of cytokine production GO:0001819 10.21 TNF IL1B IL1A IL10 CARD9
35 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 10.2 CLEC7A IL1B TNF
36 positive regulation of mitotic nuclear division GO:0045840 10.19 TNF IL1B IL1A
37 liver regeneration GO:0097421 10.19 TNF IL6 IL10
38 positive regulation of vascular endothelial growth factor production GO:0010575 10.19 IL1A IL1B IL6
39 positive regulation of interleukin-2 production GO:0032743 10.19 IL1B IL1A CLEC7A CD4
40 negative regulation of neurogenesis GO:0050768 10.18 TNF IL6 IL1B
41 response to lipopolysaccharide GO:0032496 10.18 TNF TLR4 TLR2 SLPI IL1B IL1A
42 antifungal innate immune response GO:0061760 10.16 CARD9 CLEC7A DEFB4A
43 positive regulation of glial cell proliferation GO:0060252 10.15 TNF IL6 IL1B
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.14 TNF IL1B IL10
45 positive regulation of neuroinflammatory response GO:0150078 10.11 TNF IL6 IL1B
46 positive regulation of chemokine production GO:0032722 10.11 TNF TLR4 TLR2 IL6 IL1B CARD9
47 negative regulation of lipid storage GO:0010888 10.1 TNF IL6 CRP
48 vascular endothelial growth factor production GO:0010573 10.06 IL1B IL6 TNF
49 cell activation GO:0001775 10.05 TNF TLR2 CLEC7A
50 negative regulation of cytokine production involved in immune response GO:0002719 10.04 TNF IL10

Molecular functions related to Vaginal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.44 TNF IL6 IL1B IL1A IL17A IL10
2 lipopolysaccharide immune receptor activity GO:0001875 9.26 TLR4 TLR2

Sources for Vaginal Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....